| Literature DB >> 35664364 |
Joon Hyun Cho1, Ki Young Lim1, Eun Jung Lee1, Si Hyung Lee2.
Abstract
BACKGROUND: Although premalignant duodenal lesions such as adenomas are uncommon, the incidences of these lesions have increased in recent times, and thus, the demand for minimally invasive treatments such as endoscopic resection (ER) has also increased. However, ER in the duodenum is more challenging than ER in other locations of the gastrointestinal tract. AIM: To evaluate the safety and efficacy of ER for superficial nonampullary duodenal epithelial tumors (SNADETs).Entities:
Keywords: Adenoma; Duodenum; Endoscopic mucosal resection; Endoscopic resection; Superficial nonampullary duodenal epithelial tumor
Year: 2022 PMID: 35664364 PMCID: PMC9131840 DOI: 10.4240/wjgs.v14.i4.329
Source DB: PubMed Journal: World J Gastrointest Surg
Baseline characteristics of the study subjects
|
|
|
| Median age, yr (range) | 57 (26-77) |
| Male, | 30 (53.6) |
| Number of lesions, | |
| 1 | 54 (96.4) |
| 2 | 2 (3.6) |
| Medications, | |
| Aspirin | 3 (5.3) |
| Clopidogrel | 1 (1.8) |
| Dual antiplatelets | 2 (3.6) |
| Anticoagulants | 0 |
| NSAIDs | 0 |
| Patients that underwent colonoscopy | 39 (69.6) |
| Colonoscopy positive for adenoma | 18 (46.2) |
|
|
|
| Location, | |
| Bulb | 9 (15.5) |
| Second portion | 47 (81.0) |
| Third portion | 2 (3.4) |
| Macroscopic type, | |
| Ip | 10 (17.2) |
| Is | 24 (41.4) |
| IIa or IIb | 24 (41.4) |
| Biopsy diagnosis, | |
| Adenoma/LGD | 55 (94.8) |
| Adenoma/HGD | 2 (3.4) |
| Adenocarcinoma | 1 (1.7) |
NSAID: Nonsteroidal anti-inflammatory drug; LGD: Low-grade dysplasia; HGD: High-grade dysplasia.
Endoscopic treatment and complications for the 58 lesions
| Treatment methods, | |
| EMR | 57 (98.3) |
| Snare polypectomy | 1 (1.7) |
| Lesion size, mm, | |
| Size < 10 | 20 (34.5) |
| 10 ≤ size < 15 | 26 (44.8) |
| 15 ≤ size < 20 | 7 (12.1) |
| 20 ≤ size | 5 (8.6) |
| Results of resection, | |
|
| 39 (67.2) |
| Piecemeal | 19 (32.8) |
| Adjunctive coagulation, | 29 (50.0) |
| Prophylactic clip placement, | 48 (82.8) |
| Complication, | |
| Intraprocedural bleeding | 16 (27.6) |
| Delayed bleeding | 1 (1.7) |
| Perforation | 0 (0) |
EMR: Endoscopic mucosal resection.
Histopathologic results for the 58 lesions
| Tumor size, mm, median (range) | 12 (4–20) |
| Final pathology, | 57 (98.3) |
| Adenoma/LGD | 52 (89.7) |
| Adenoma/HGD | 3 (5.2) |
| Intramucosal adenocarcinoma | 3 (5.2) |
| Lateral margin, | |
| Negative | 36 (62.1) |
| Positive | 3 (5.2) |
| Inconclusive | 19 (32.8) |
| Vertical margin, | |
| Negative | 50 (86.2) |
| Positive | 0 (0) |
| Inconclusive | 8 (13.8) |
| Complete (R0) resection | 36 (62.1) |
LGD: Low-grade dysplasia; HGD: High-grade dysplasia.
Factors associated with endoscopic mucosal resection -related bleeding
|
|
|
|
|
| Antiplatelet use | 0.661 | ||
| Yes | 1 (14.3) | 6 (85.7) | |
| No | 16 (31.4) | 35 (68.6) | |
| Lesion size, mm, |
| ||
| Size < 10 | 1 (5.0) | 19 (95.0) | |
| 10 ≤ size < 15 | 8 (30.8) | 18 (69.2) | |
| 15 ≤ size < 20 | 4 (57.1) | 3 (42.9) | |
| 20 ≤ size | 4 (80.0) | 1 (20.0) | |
| Results of resection, | 0.218 | ||
|
| 9 (23.1) | 30 (76.9) | |
| Piecemeal | 8 (42.1) | 11 (57.9) | |
| Location, | 0.855 | ||
| Bulb | 2 (22.2) | 7 (77.8) | |
| Second portion | 15 (31.9) | 32 (68.1) | |
| Third portion | 0 (0) | 2 (100) | |
| Macroscopic type, | 0.950 | ||
| Ip | 2 (20.0) | 8 (80.0) | |
| Is | 7 (29.2) | 17 (70.8) | |
| IIa or IIb | 8 (33.3) | 16 (66.7) | |
| Final pathology | 0.345 | ||
| Adenoma/LGD | 14 (26.9) | 38 (73.1) | |
| Adenoma/HGD and adenocarcinoma | 3 (50.0) | 3 (50.0) |
LGD: Low-grade dysplasia; HGD: High-grade dysplasia
Clinicopathologic data and outcomes for 3 cases of incomplete resection
|
|
|
|
|
|
|
|
|
|
|
| 1 | 72 | Bulb | 20 | Intramucosal adenocarcinoma |
| EMR |
|
| 29 |
| 2 | 71 | Bulb | 20 | LGD |
| EMR |
|
| 27 |
| 3 | 75 | 2nd portion | 10 | LGD |
| EMR |
|
| 17 |
LGD: Low-grade dysplasia; EMR: Endoscopic mucosal resection.
Long-term outcomes (n = 50 patients and 52 lesions)
| Recurrence, | 0 (0%) |
| Death by duodenal neoplasm | 0 (0%) |
| All-cause mortality | 2 (3.6%) |
| Follow-up period median (range) | 23 (6-100) mo |
| No. of follow-up endoscopies | |
| 2 | 9 |
| 3 or 4 | 28 |
| 5 ≤ | 13 |